Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | RB1 loss |
Therapy | Sirolimus |
Indication/Tumor Type | neuroendocrine tumor |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RB1 loss | neuroendocrine tumor | sensitive | Sirolimus | Preclinical | Actionable | In a preclinical study, Sirolimus (rapamycin) slowed pituitary tumors and decreased the occurrence of thyroid tumors in Rb1+/- mice (PMID: 23454836). | 23454836 |
PubMed Id | Reference Title | Details |
---|---|---|
(23454836) | Rapamycin extends life span of Rb1+/- mice by inhibiting neuroendocrine tumors. | Full reference... |